CIK 0001937653 · Non-accelerated filer<br>Smaller reporting company
Zymeworks Inc.
Sign in to watch- Ticker
- ZYME
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 883099146
- Phone
- 302-274-8744
- Business address
- 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
- Former names
- Zymeworks Delaware Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $357,557
- in 1 filing
Net −$357,557. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-10 | Mahony Susan Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2024-12-10 | Gallagher Neil Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2024-09-01 | PATTERSON LEONE D EVP, Chief Bus & Fin Officer | Grant or award · Stock Option (Right to Buy) | +360,000 | 360,000 | ||
| 2024-04-02 | Gallagher Neil Director | Grant or award · Stock Option (Right to Buy) | +74,000 | 74,000 | ||
| 2024-02-08 | Cesano Alessandra Director | Grant or award · Stock Option (Right to Buy) | +74,000 | 74,000 | ||
| 2024-01-08 | Galbraith Kenneth Chair & CEO | Sale | −5,706 | $11.22 | $64K | 23,762 |
| 2024-01-08 | Astle Christopher SVP & Chief Financial Officer | Sale | −1,431 | $11.22 | $16K | 6,503 |
| 2024-01-08 | Moore Paul Andrew Chief Scientific Officer | Sale | −2,339 | $11.22 | $26K | 7,367 |
| 2024-01-05 | Galbraith Kenneth Chair & CEO | Option exercise | +47,666 | 47,666 | ||
| 2024-01-05 | Galbraith Kenneth Chair & CEO | Sale | −18,198 | $10.65 | $194K | 29,468 |
| 2024-01-05 | Galbraith Kenneth Chair & CEO | Option exercise · Restricted Stock Unit | −47,666 | 95,334 | ||
| 2024-01-05 | Galbraith Kenneth Chair & CEO | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-01-05 | Galbraith Kenneth Chair & CEO | Grant or award · Restricted Stock Unit | +200,000 | 200,000 | ||
| 2024-01-05 | Astle Christopher SVP & Chief Financial Officer | Option exercise | +10,500 | 12,497 | ||
| 2024-01-05 | Astle Christopher SVP & Chief Financial Officer | Sale | −4,563 | $10.65 | $49K | 7,934 |
| 2024-01-05 | Astle Christopher SVP & Chief Financial Officer | Option exercise · Restricted Stock Unit | −10,500 | 21,000 | ||
| 2024-01-05 | Astle Christopher SVP & Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2024-01-05 | Astle Christopher SVP & Chief Financial Officer | Grant or award · Restricted Stock Unit | +30,000 | 30,000 | ||
| 2024-01-05 | Moore Paul Andrew Chief Scientific Officer | Option exercise | +17,166 | 17,166 | ||
| 2024-01-05 | Moore Paul Andrew Chief Scientific Officer | Sale | −7,460 | $10.65 | $79K | 9,706 |
Page 8 of 12 · 224 trades